Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
September 29th 2023The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Read More
Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines
August 12th 2023Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.
Read More
ASCO 2023: Leukemia and Lymphoma
July 31st 2023Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Read More
Disparities in Germline Genetic Testing Rates Exist, but Mechanisms Remain Unclear
June 9th 2023Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, discussed the importance of germline genetic testing in patients with triple-negative breast cancer and other cancer types.
Read More
ZUMA-7 Findings Show Earlier Is Better for Axi-Cel Use in R/R LBCL, Says Dr Jason Westin
June 5th 2023Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.
Read More
Dr Judy Wang on the Potential of CLN-619 for the Treatment of Solid Tumors
June 5th 2023Judy Wang, MD, medical oncologist and clinical trials investigator at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, discussed the mechanism of action and rationale for studying CLN-619, an anti-MICA/B antibody, with and without pembrolizumab in patients with solid tumors.
Read More
Dr Bhagirathbhai Dholaria Discusses TRiMM-2 Trial Findings
June 4th 2023Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.
Read More
Social Determinants of Health Impact Germline Testing Rates Among Patients With TNBC
June 4th 2023Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Read More
Dr Dennis Slamon on What Sets the NATALEE Trial Apart From Other Breast Cancer Studies
June 3rd 2023Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
Read More